Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Humacyte, Inc. (HUMA) announces the pricing of a public offering, with 13.4 million shares of common stock at $3.00 per share, aiming to raise $40.2 million.
The public offering of 13.4 million shares by Humacyte at $3.00 per share is a strategic move aimed at raising capital, with expected gross proceeds of $40.2 million. This influx of capital is crucial for the company's ongoing research and development efforts, particularly as a clinical-stage biotechnology firm where funding is vital for sustaining operations and advancing clinical trials. The pricing of the shares, however, reflects the market's current valuation of the company, which investors should scrutinize in relation to its pipeline potential, cash burn rate and the competitive landscape.
Investors should consider the dilutive effect of this offering on existing shares. While it provides necessary capital, it also means that current shareholders will own a smaller percentage of the company post-offering. It's essential to evaluate the use of proceeds, as efficient allocation towards high-potential projects can enhance long-term value, whereas misallocation could lead to underperformance.
Humacyte's focus on developing universally implantable bioengineered human tissue places it within a niche but rapidly growing segment of the biotechnology industry. The success of such an offering can serve as a bellwether for investor confidence in regenerative medicine. The capital raised could accelerate the company's path to potentially bringing innovative treatments to market, which would have significant implications for healthcare providers and patients alike.
Market trends show increasing interest in personalized and regenerative medicine and Humacyte's proprietary technology could position it well within this space. However, the path to commercialization is fraught with regulatory hurdles and clinical trial risks. The market will watch closely for progress updates post-capital raise, as these will be critical indicators of the company's ability to execute on its business plan and deliver on its scientific promises.
In transactions such as public offerings, legal compliance with securities regulations is paramount. The underwriting discounts and commissions, along with other offering expenses, will be scrutinized by legal professionals to ensure adherence to SEC guidelines. Furthermore, the timing and conditions of the closing will be subject to legal review to safeguard the interests of both the company and the investors.
It is also important to note that the disclosure of offering details and the use of proceeds in public filings provides transparency, which is a cornerstone of investor protection. The legal framework governing such offerings aims to balance the company's need to raise capital with the protection of investors, ensuring that all material information is disclosed for informed decision-making.
02/29/2024 - 09:18 PM
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced today announced the pricing of an underwritten public offering of 13,400,000 shares of its common stock at a public offering price of $3.00 per share. The aggregate gross proceeds from this offering are expected to be $40.2 million , before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,010,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
TD Cowen and Cantor are acting as joint book-running managers for the offering. BTIG is acting as lead manager.
Humacyte intends to use the net proceeds that it will receive from the offering to continue the advancement of its pipeline in regenerative medicine, to support U.S. Food and Drug Administration’s (“FDA”) review of its Biologics License Application (“BLA”) seeking approval of Humacyte’s bioengineered human acellular vessels (“HAVs”) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible, to establish its initial commercial infrastructure in anticipation of future potential commercial launches and for general corporate purposes.
A shelf registration statement on Form S-3 (No. 333-267225) was previously filed with the Securities and Exchange Commission (“SEC”) on September 1, 2022 and declared effective by the SEC on September 9, 2022. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on February 29, 2024 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that Humacyte has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about Humacyte and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or Cantor Fitzgerald & Co, Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022 or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of HAVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (“AV”) access for hemodialysis, and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (“RMAT”) designation and has also received FDA Fast Track designation. Humacyte’s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received an RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the success of the offering; the anticipated use of proceeds from the offering; the implementation of Humacyte’s business model and strategic plans for its business; and the timing or likelihood of regulatory filings, acceptances and approvals, including the BLA seeking approval of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible. Humacyte cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended December 31, 2022 and in its subsequently filed Quarterly Reports on Form 10-Q, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.
Humacyte Investor Contact: jallaire@lifesciadvisors.com investors@humacyte.com
Humacyte Media Contact: rich@precisionstrategies.com media@humacyte
What did Humacyte, Inc. (HUMA) announce regarding a public offering?
Humacyte, Inc. (HUMA) announced the pricing of an underwritten public offering of 13,400,000 shares of its common stock at a public offering price of $3.00 per share.
How many shares of common stock were offered by Humacyte, Inc. (HUMA) in the public offering?
Humacyte, Inc. (HUMA) offered 13,400,000 shares of its common stock in the public offering.
What was the public offering price per share set by Humacyte, Inc. (HUMA)?
The public offering price per share set by Humacyte, Inc. (HUMA) was $3.00.
How much is Humacyte, Inc. (HUMA) expecting to raise from the public offering?
Humacyte, Inc. (HUMA) is expecting to raise $40.2 million from the public offering.
When is the closing of the public offering expected to occur for Humacyte, Inc. (HUMA)?
The closing of the public offering is expected to occur on or
